UPDATE: Cowen Starts Ohr Pharmaceutical (OHRP) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Ohr Pharmaceutical (OHRP) Presents Additional Data from IMPACT Study; Shows Early Regression of SHRM in wet-AMD
March 2, 2015 7:34 AM ESTOhr Pharmaceutical (Nasdaq: OHRP) announced the presentation of new data from the IMPACT study interim analysis at the 38th Annual Macula Society Meeting which took place February 25-28th, in Scottsdale, Arizona. The new data show an early regression of subretinal hyper-reflective material (SHRM), an anatomic biomarker for the wet form of age-related macular degeneration (wet-AMD), which is consistent with the early gains in visual acuity previously reported from this study. The data were presented by Jason S. Slakter, MD, Chief Medical Officer at Ohr and Clinical Professor of Ophthalmology, NYU School of... More
Roth Capital Starts Ohr Pharmaceutical (OHRP) at Buy
February 26, 2015 7:10 AM ESTRoth Capital initiated coverage on Ohr Pharmaceutical (NASDAQ: OHRP) with a Buy rating and a price target of $30.00.
For an analyst ratings summary and ratings history on Ohr Pharmaceutical click here. For more ratings news on Ohr Pharmaceutical click here.
Shares of Ohr Pharmaceutical closed at $7.02 yesterday.
... More